-Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (Daclizumab)

Abstract

Pure red-cell aplasia is an autoimmune disease. The authors treated 15 affected patients with 5 weekly injections of a humanized monoclonal antibody to the interleukin-2 receptor (daclizumab). Six patients (40%) responded to treatment. All responders became transfusion-independent and achieved normal or near-normal hemoglobin values and normal reticulocyte counts. In this small study, daclizumab did not have adverse effects